Kymera Therapeutics (KYMR) Tops Q1 EPS by 17c
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Join SI Premium – FREE
Kymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.17 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $34.36 million versus the consensus estimate of $8.01 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- AI/ML Innovations plans $2M private placement on the CSE
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
